Respiratory medicine
-
Respiratory medicine · Oct 2013
Randomized Controlled Trial Multicenter StudySafety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN study.
QVA149 is an inhaled, once-daily fixed-dose dual bronchodilator combination of the long-acting β2-agonist indacaterol and long-acting muscarinic antagonist glycopyrronium (NVA237) for the treatment of chronic obstructive pulmonary disease (COPD). We investigated the safety and efficacy of QVA149 over 52 weeks. ⋯ QVA149 demonstrated a good safety and tolerability profile, providing rapid and sustained bronchodilation over 52 weeks in patients with moderate-to-severe COPD. ClinicalTrials.gov identifier: NCT01120717.
-
Respiratory medicine · Oct 2013
Randomized Controlled Trial Multicenter StudyEfficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD.
To examine the efficacy and safety of the once-daily, inhaled, long-acting muscarinic antagonist/β2-agonist combination umeclidinium/vilanterol (UMEC/VI) compared with UMEC and VI monotherapies in patients with chronic obstructive pulmonary disease (COPD). ⋯ Once-daily UMEC/VI 62.5/25 mcg was well tolerated and provided clinically-significant improvements in lung function and symptoms in patients with COPD.